Beta-Blockers in Asymptomatic Coronary Artery Disease
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- Servier
- Janssen Pharmaceutica
- GlaxoSmithKline
- Merck Sharp and Dohme United Kingdom
- Novartis
- Medicines Company
- Roche
- Otsuka America
- AstraZeneca
- Institut National de la Santé et de la Recherche Médicale (U-1148)
- Medtronic
- Eli Lilly and Company
- Pfizer
- Boehringer Ingelheim
- Sanofi
This publication has 22 references indexed in Scilit:
- Benefit of β-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary interventionHeart, 2014
- Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trialThe Lancet, 2005
- Age and lack of β-blocker therapy are associated with increased long-term mortality after primary coronary angioplasty for acute myocardial infarctionInternational Journal of Cardiology, 2003
- Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart FailureCirculation, 2002
- Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trialThe Lancet, 2001
- beta Blockade after myocardial infarction: systematic review and meta regression analysisBMJ, 1999
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1981